Inhibikase Therapeutics (IKT) PE Ratio: History & Chart

Inhibikase Therapeutics, Inc.(IKT)

Biotechnology · Wilmington, DE

$1.98-0.02 (-1.00%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Wilmington, DE

35 employees

www.inhibikase.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark T. Iwicki

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Inhibikase Therapeutics, Inc. (IKT)	$261.43M	N/A	N/A	N/A	N/A
X4 Pharmaceuticals, Inc. (XFOR)vs ›	$261.27M	N/A	4.20	4.20	4.20
TriSalus Life Sciences, Inc. (TLSI)vs ›	$262.92M	N/A	175.46	175.46	175.46
OraSure Technologies, Inc. (OSUR)vs ›	$259.56M	N/A	16.07	13.93	35.67
Treace Medical Concepts, Inc. (TMCI)vs ›	$259.49M	N/A	N/A	N/A	N/A
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$259.14M	N/A	N/A	N/A	N/A
Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›	$259.12M	N/A	N/A	N/A	N/A
Palisade Bio, Inc. (PALI)vs ›	$258.63M	N/A	4.44	4.44	4.44
Scribe Therapeutics Inc. (SCTX)vs ›	$264.25M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$265.78M	N/A	15.73	15.73	15.86

NAME

MARKET CAP

PE RATIO

TTM

Inhibikase Therapeutics, Inc. (IKT)

$261.43M

N/A

X4 Pharmaceuticals, Inc. (XFOR)vs ›

$261.27M

N/A

4.20

TriSalus Life Sciences, Inc. (TLSI)vs ›

$262.92M

N/A

175.46

OraSure Technologies, Inc. (OSUR)vs ›

$259.56M

N/A

16.07

13.93

35.67

Treace Medical Concepts, Inc. (TMCI)vs ›

$259.49M

N/A

Eupraxia Pharmaceuticals Inc. (EPRX)vs ›

$259.14M

N/A

Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›

$259.12M

N/A

Palisade Bio, Inc. (PALI)vs ›

$258.63M

N/A

4.44

Scribe Therapeutics Inc. (SCTX)vs ›

$264.25M

N/A

EyePoint Pharmaceuticals, Inc. (EYPT)vs ›

$265.78M

N/A

15.73

15.86

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

IKT PE Ratio Metrics

IKT Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics